Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/36031
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Adelstein S. | en |
dc.contributor.author | Nguyen M. | en |
dc.contributor.author | Corte T.J. | en |
dc.contributor.author | Jee A.S. | en |
dc.contributor.author | Sahhar J. | en |
dc.contributor.author | Youssef P. | en |
dc.contributor.author | Bleasel J. | en |
dc.date.accessioned | 2021-05-14T12:12:25Z | en |
dc.date.available | 2021-05-14T12:12:25Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20190917 | en |
dc.date.issued | 2019-09-17 | en |
dc.identifier.citation | Pharmacology and Therapeutics. 202 (pp 40-52), 2019. Date of Publication: October 2019. | en |
dc.identifier.issn | 0163-7258 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/36031 | en |
dc.description.abstract | Disease behaviour in interstitial lung disease (ILD) is highly variable and accurate clinical tools to predict prognosis and guide management decisions remain unsatisfactorily elusive. Accurate disease stratification would allow clinicians to better distinguish patients at risk of rapid progression requiring urgent treatment, from those indolent disease where potentially toxic drug therapy could be minimised or avoided. Several serum biomarkers have demonstrated potential utility for diagnosis and prognosis of ILD in small retrospective studies, and the hope is future multicentre prospective trials focussed on the markers with most potential will see translation to clinical practice. Two important and contrasting fibrotic lung diseases with high mortality are idiopathic pulmonary fibrosis (IPF) and systemic sclerosis associated ILD (SSc-ILD). In this era where anti-fibrotics for IPF have proven benefit, there are increasing biologic and non-biologic options for the treatment of connective tissue disease ILD (CTD-ILD), and the incidence of both is increasing, there is an urgent need to improve the diagnostic and prognostic accuracy in these complex patients. This comprehensive literature review will summarise and discuss the current evidence for the major candidate serum biomarkers in IPF and SSc-ILD. Biomarkers will be categorised by the following major mechanistic pathways (1) alveolar epithelial cell damage; (2) aberrant fibrogenesis, fibroproliferation and matrix remodelling; (3) immune dysregulation; and (4) vascular and endothelial damage. The aim is to review the rationale, potential and limitations of current candidate biomarkers and their utility in IPF and SSc-ILD to help direct future research and translation to clinical practice.Copyright © 2019 | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Elsevier Inc. (E-mail: usjcs@elsevier.com) | en |
dc.relation.ispartof | Pharmacology and Therapeutics | en |
dc.title | Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons. | en |
dc.type | Review | en |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.pharmthera.2019.05.014 | en |
dc.publisher.place | United States | en |
dc.identifier.pubmedid | 31153954 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31153954] | en |
dc.identifier.source | 2002106343 | en |
dc.identifier.institution | (Jee, Youssef, Bleasel, Adelstein, Nguyen, Corte) Department of Respiratory, Royal Prince Alfred Hospital, Sydney, Australia (Jee, Adelstein, Corte) Sydney Medical School, University of Sydney, Australia (Sahhar) Department of Rheumatology, Monash Health, Clayton, VIC 3168, Australia (Youssef, Bleasel) Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Australia (Adelstein, Nguyen) Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia (Adelstein, Nguyen) Immunopathology Laboratory, Southwest Sydney Pathology Service, Sydney, NSW 2050, Australia | en |
dc.description.address | A.S. Jee, Respiratory Department, Royal Prince Alfred Hospital, Level 11 Building 75, Missenden Road 2050, Camperdown, Sydney, Australia. E-mail: Adelle.Jee@health.nsw.gov.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Extracellular matrix Interstitial lung disease Precision medicine Prognostic Sensitivity Specificity | en |
dc.identifier.authoremail | Jee A.S.; Adelle.Jee@health.nsw.gov.au | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
crisitem.author.dept | Rheumatology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.